ADMA · Company research
ADMA Biologics, Inc. (ADMA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
27records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| No clotting events were reported for ADMA's immune globulin made with its updated process. - Stock Titan | No clotting events were reported for ADMA's immune globulin made with its updated process. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| ADMA Biologics Inc (ADMA) Stock Forecasts - Yahoo Finance | ADMA Biologics Inc (ADMA) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| ADMA Biologics (ADMA) Stock Still Looks Cheap Next To Its Earnings - Simply Wall Street | ADMA Biologics (ADMA) Stock Still Looks Cheap Next To Its Earnings Simply Wall Street | View source ↗ | Simply Wall Street | Oct 14, 2026 | neutral | 0 | 0.6 |
| ADMA Biologics Inc. Stock Grades | ADMA - Barron's | ADMA Biologics Inc. Stock Grades | ADMA Barron's | View source ↗ | Barron's | Oct 12, 2026 | neutral | 0 | 0.6 |
| ADMA Biologics Inc (ADMA) Stock Forecasts - Yahoo! Finance Canada | ADMA Biologics Inc (ADMA) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 11, 2026 | neutral | 0 | 0.6 |
| Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? | Intellia Therapeutics shares rallied 7.6% following FDA acceptance of its CRISPR-based HAE treatment under Priority Review with a March 2027 decision date, and a $400 million debt facility secured in September. However, the stock carries a Hold rating as earnings estimate revisions remain unchanged, and the company faces declining revenues and quarterly losses. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | neutral | 0 | 1 |
| Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? | Intellia Therapeutics shares rallied 7.6% following FDA acceptance of its CRISPR-based HAE treatment under Priority Review with a March 2027 decision date, and a $400 million debt facility secured in September. However, the stock carries a Hold rating as earnings estimate revisions remain unchanged, and the company faces declining revenues and quarterly losses. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | neutral | 0 | 1 |
| Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors | Adma Biologics (ADMA) outperformed the broader market on October 8, 2026, rising 1.87% to $10.33 while the S&P 500 declined 0.47%. The infectious disease drug developer has gained 7.3% over the past month and is expected to report EPS of $0.19 (up 18.75% YoY) with revenue of $139.8 million (up 4.16% YoY). The company trades at a Forward P/E of 13.06, a discount to its industry average of 23.26, and currently holds a Zacks Rank of #3 (Hold). | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors | Adma Biologics (ADMA) outperformed the broader market on October 8, 2026, rising 1.87% to $10.33 while the S&P 500 declined 0.47%. The infectious disease drug developer has gained 7.3% over the past month and is expected to report EPS of $0.19 (up 18.75% YoY) with revenue of $139.8 million (up 4.16% YoY). The company trades at a Forward P/E of 13.06, a discount to its industry average of 23.26, and currently holds a Zacks Rank of #3 (Hold). | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| ADMA Oct 2026 15.000 call (ADMA261016C00015000) Stock Price, News, Quote & History - Yahoo! Finance Canada | ADMA Oct 2026 15.000 call (ADMA261016C00015000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 8, 2026 | neutral | 0 | 0.6 |
| ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know | ADMA Biologics has attracted investor attention with shares returning +7.3% over the past month, outperforming the S&P 500's +1.4% gain. The company is expected to post earnings of $0.19 per share for the current quarter (+18.8% YoY) and $0.78 for the fiscal year (+30% YoY). However, with a Zacks Rank #3 (Hold) rating and consensus estimates remaining unchanged over the past month, the stock is expected to perform in line with the broader market in the near term. The company trades at a valuation discount to peers with a B grade on the Value Style Score. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know | ADMA Biologics has attracted investor attention with shares returning +7.3% over the past month, outperforming the S&P 500's +1.4% gain. The company is expected to post earnings of $0.19 per share for the current quarter (+18.8% YoY) and $0.78 for the fiscal year (+30% YoY). However, with a Zacks Rank #3 (Hold) rating and consensus estimates remaining unchanged over the past month, the stock is expected to perform in line with the broader market in the near term. The company trades at a valuation discount to peers with a B grade on the Value Style Score. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know | ADMA Biologics has attracted investor attention with shares returning +7.3% over the past month, outperforming the S&P 500's +1.4% gain. The company is expected to post earnings of $0.19 per share for the current quarter (+18.8% YoY) and $0.78 for the fiscal year (+30% YoY). However, with a Zacks Rank #3 (Hold) rating and consensus estimates remaining unchanged over the past month, the stock is expected to perform in line with the broader market in the near term. The company trades at a valuation discount to peers with a B grade on the Value Style Score. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| ADMA Oct 2026 16.000 call (ADMA261016C00016000) Stock Price, News, Quote & History - Yahoo! Finance Canada | ADMA Oct 2026 16.000 call (ADMA261016C00016000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 8, 2026 | neutral | 0 | 0.6 |
| ADMA Oct 2026 9.000 call (ADMA261016C00009000) Stock Price, News, Quote & History - Yahoo! Finance Canada | ADMA Oct 2026 9.000 call (ADMA261016C00009000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 7, 2026 | neutral | 0 | 0.6 |
| ADMA Biologics (Nasdaq:ADMA) - Stock Analysis - Simply Wall Street | ADMA Biologics (Nasdaq:ADMA) - Stock Analysis Simply Wall Street | View source ↗ | Simply Wall Street | Oct 5, 2026 | neutral | 0 | 0.6 |
| ADMA Biologics Inc (ADMA) Stock Forecasts - Yahoo Finance | ADMA Biologics Inc (ADMA) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 4, 2026 | neutral | 0 | 0.6 |
| Here's Why Adma Biologics (ADMA) Fell More Than Broader Market - Yahoo Finance | Here's Why Adma Biologics (ADMA) Fell More Than Broader Market Yahoo Finance | View source ↗ | Yahoo Finance | Sep 29, 2026 | neutral | 0 | 0.6 |
| ADMA Biologics (ADMA) Stock Still Looks Reasonable Given Its Earnings Power - Simply Wall Street | ADMA Biologics (ADMA) Stock Still Looks Reasonable Given Its Earnings Power Simply Wall Street | View source ↗ | Simply Wall Street | Sep 25, 2026 | neutral | 0 | 0.6 |
| ADMA Biologics (NasdaqGM:ADMA) Stock Forecast & Analyst Predictions - Simply Wall Street | ADMA Biologics (NasdaqGM:ADMA) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 21, 2026 | neutral | 0 | 0.6 |
| Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance | Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know Yahoo Finance | View source ↗ | Yahoo Finance | Sep 18, 2026 | neutral | 0 | 0.6 |
| Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance | Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know Yahoo Finance | View source ↗ | Yahoo Finance | Sep 11, 2026 | neutral | 0 | 0.6 |
| ADMA Stock Drop: ADMA Biologics Channel Stuffing Allegations Lead to 29% Stock Drop and Securities Fraud Class Action for Investors - PR Newswire | ADMA Stock Drop: ADMA Biologics Channel Stuffing Allegations Lead to 29% Stock Drop and Securities Fraud Class Action for Investors PR Newswire | View source ↗ | PR Newswire | Aug 4, 2026 | neutral | 0 | 0.6 |
| Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance | Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note Yahoo Finance | View source ↗ | Yahoo Finance | Jul 31, 2026 | neutral | 0 | 0.6 |
| Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance | Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note Yahoo Finance | View source ↗ | Yahoo Finance | Jul 21, 2026 | neutral | 0 | 0.6 |
| ADMA Biologics (ADMA) Stock Looks Undervalued Even After A 5 Year Run - Yahoo Finance | ADMA Biologics (ADMA) Stock Looks Undervalued Even After A 5 Year Run Yahoo Finance | View source ↗ | Yahoo Finance | Jul 15, 2026 | neutral | 0 | 0.6 |
| Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance | Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know Yahoo Finance | View source ↗ | Yahoo Finance | Jun 29, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.